DnB Asset Management AS Has $813,000 Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

DnB Asset Management AS decreased its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 35.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,687 shares of the biotechnology company’s stock after selling 3,719 shares during the quarter. DnB Asset Management AS’s holdings in Sarepta Therapeutics were worth $813,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. New Age Alpha Advisors LLC acquired a new stake in Sarepta Therapeutics in the 4th quarter worth about $8,553,000. Norges Bank bought a new position in shares of Sarepta Therapeutics during the fourth quarter worth approximately $126,315,000. NEOS Investment Management LLC raised its position in shares of Sarepta Therapeutics by 13.9% in the fourth quarter. NEOS Investment Management LLC now owns 1,943 shares of the biotechnology company’s stock valued at $236,000 after buying an additional 237 shares in the last quarter. Sava Infond d.o.o. bought a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $365,000. Finally, WINTON GROUP Ltd bought a new position in Sarepta Therapeutics during the 4th quarter worth $678,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SRPT has been the topic of several analyst reports. HC Wainwright raised Sarepta Therapeutics from a “sell” rating to a “neutral” rating and set a $75.00 target price on the stock in a report on Wednesday. Scotiabank reduced their target price on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating on the stock in a report on Thursday, March 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $163.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Deutsche Bank Aktiengesellschaft reduced their price objective on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a research note on Wednesday, March 19th. Finally, Needham & Company LLC reissued a “buy” rating and set a $202.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Six analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $164.05.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $62.47 on Thursday. The stock’s 50 day moving average is $99.40 and its 200 day moving average is $114.66. Sarepta Therapeutics, Inc. has a one year low of $58.50 and a one year high of $173.25. The firm has a market cap of $6.06 billion, a P/E ratio of 49.98 and a beta of 0.79. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Insider Transactions at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares of the company’s stock, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.